Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
20 hedge funds and large institutions have $41.9M invested in Iterum Therapeutics in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 12 reducing their positions, and 0 closing their positions.
5% more funds holding
Funds holding: 19 → 20 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.03% less ownership
Funds ownership: 2.85% → 2.82% (-0.03%)
14% less capital invested
Capital invested by funds: $48.8M → $41.9M (-$6.92M)
83% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$7.89K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$778 |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$334 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$170K |
| 2 |
NA
Neuburgh Advisers
Los Angeles,
California
|
-$57.9K |
| 3 |
FCM
Flinton Capital Management
Philadelphia,
Pennsylvania
|
-$47.8K |
| 4 |
Franklin Resources
San Mateo,
California
|
-$44.1K |
| 5 |
TAM
Tyers Asset Management
Austin,
Texas
|
-$37.5K |
ITRM Hedge Fund Activity: Q2 2019 in Review
20 of the 4,564 institutional investors tracked by Wall St. Rank reported a position in Iterum Therapeutics (ITRM) for Q2 2019, worth a combined $41.9M — down 14% from $48.8M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ITRM positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 12 trimmed.
The largest buyer was Granahan Investment Management, adding an estimated $7.89K. The largest seller was Tiverton Asset Management, cutting an estimated $170K.
- 20 institutional investors held Iterum Therapeutics (ITRM) as of Q2 2019, up from 19 in Q1 2019.
- Funds reported $41.9M of Iterum Therapeutics stock for Q2 2019, down 14% quarter-over-quarter.
- 1 fund opened new Iterum Therapeutics positions in Q2 2019 and 0 closed out, a net change of +1 holder.
- The largest Iterum Therapeutics buyer in Q2 2019 was Granahan Investment Management, an estimated $7.89K added.
- The largest Iterum Therapeutics seller in Q2 2019 was Tiverton Asset Management, an estimated $170K sold.
Based on aggregated 13F filings for Q2 2019.